Subtopic Deep Dive

Hypericum Perforatum Pharmacology
Research Guide

What is Hypericum Perforatum Pharmacology?

Hypericum perforatum pharmacology studies the pharmacological actions, pharmacokinetics, mechanisms, and clinical effects of bioactive compounds like hyperforin and hypericin from St. John's wort.

Research examines antidepressant efficacy, cytochrome P450 inhibition, and antibacterial properties of Hypericum perforatum extracts. Key papers include Linde et al. (2008) with 471 citations on depression treatment and Chatterjee et al. (1998) with 444 citations identifying hyperforin as an active antidepressant component. Over 10 highly cited papers from 1998-2010 establish core findings on neurotransmitter modulation and drug interactions.

Curated Papers

Key Challenges

Why It Matters

Hypericum perforatum pharmacology informs clinical use of St. John's wort as an herbal antidepressant with fewer side effects than standard drugs, as shown in Linde et al. (2008) meta-analysis of trials. It highlights critical herb-drug interactions via CYP enzyme inhibition (Obach, 2000) and warfarin pharmacokinetics alterations (Jiang et al., 2004), guiding safe polypharmacy. Antibacterial applications against multiresistant bacteria (Schempp et al., 1999; Saddiqe et al., 2010) support its role in antimicrobial resistance strategies.

Key Research Challenges

Standardized Extract Variability

Hypericum extracts vary in hyperforin and hypericin content, complicating reproducible clinical outcomes. Linde et al. (2008) noted inconsistent trial results due to extract differences. Butterweck (2003) emphasized need for standardized preparations in mechanism studies.

Cytochrome P450 Interaction Prediction

Predicting herb-drug interactions from in vitro CYP inhibition data remains challenging for clinical translation. Obach (2000) identified multiple CYP enzymes affected, but Borrelli and Izzo (2009) reported variable patient outcomes. Jiang et al. (2004) showed inconsistent warfarin effects requiring better models.

Antidepressant Mechanism Elucidation

Multiple proposed mechanisms like serotonin uptake inhibition by hyperforin (Singer et al., 1999) coexist without consensus. Chatterjee et al. (1998) proposed hyperforin as key, while Butterweck (2003) reviewed neurotransmitter and neuroendocrine pathways. Di Carlo et al. (2001) highlighted unresolved monoamine oxidase interactions.

Essential Papers

St John's wort for major depression

Klaus Linde, Michael M. Berner, Levente Kriston · 2008 · Cochrane Database of Systematic Reviews · 471 citations

The available evidence suggests that the hypericum extracts tested in the included trials a) are superior to placebo in patients with major depression; b) are similarly effective as standard antide...

Hyperforin as a possible antidepressant component of hypericum extracts

S. S. Chatterjee, S.K. Bhattacharya, Meinolf Wonnemann et al. · 1998 · Life Sciences · 444 citations

Inhibition of Human Cytochrome P450 Enzymes by Constituents of St. John's Wort, an Herbal Preparation Used in the Treatment of Depression

R. Scott Obach · 2000 · Journal of Pharmacology and Experimental Therapeutics · 400 citations

A review of the antibacterial activity of Hypericum perforatum L.

Zeb Saddiqe, Ismat Naeem, Alya Maimoona · 2010 · Journal of Ethnopharmacology · 380 citations

Mechanism of Action of St John???s Wort in Depression

Veronika Butterweck · 2003 · CNS Drugs · 367 citations

St John's wort: Prozac from the plant kingdom

Giulia Di Carlo, Francesca Borrelli, Edzard Ernst et al. · 2001 · Trends in Pharmacological Sciences · 274 citations

Herb–Drug Interactions with St John’s Wort (Hypericum perforatum): an Update on Clinical Observations

Francesca Borrelli, Angelo A. Izzo · 2009 · The AAPS Journal · 274 citations

Reading Guide

Foundational Papers

Start with Linde et al. (2008) for clinical efficacy evidence, Chatterjee et al. (1998) for hyperforin identification, and Obach (2000) for drug interaction mechanisms, as they anchor depression, active compounds, and safety profiles with highest citations.

Recent Advances

Study Butterweck (2003) on action mechanisms, Borrelli and Izzo (2009) on interaction updates, and Saddiqe et al. (2010) on antibacterial activity for post-2000 advances.

Core Methods

Core techniques are systematic reviews/meta-analyses (Linde et al., 2008), radioligand binding/uptake assays (Singer et al., 1999; Chatterjee et al., 1998), enzyme inhibition kinetics (Obach, 2000), and clinical pharmacokinetic crossovers (Jiang et al., 2004).

How PapersFlow Helps You Research Hypericum Perforatum Pharmacology

Discover & Search

PapersFlow's Research Agent uses searchPapers and citationGraph to map high-citation clusters around Linde et al. (2008, 471 citations), revealing antidepressant efficacy literature, then findSimilarPapers expands to mechanism studies like Chatterjee et al. (1998). exaSearch uncovers niche antibacterial papers such as Schempp et al. (1999) on multiresistant Staphylococcus aureus.

Analyze & Verify

Analysis Agent applies readPaperContent to extract pharmacokinetics data from Jiang et al. (2004), verifies claims with CoVe against Obach (2000) CYP inhibition results, and uses runPythonAnalysis for meta-analysis of GRADE-scored trial outcomes from Linde et al. (2008). Statistical verification confirms side effect reductions via pandas-based effect size calculations.

Synthesize & Write

Synthesis Agent detects gaps in interaction studies between Borrelli and Izzo (2009) and recent trials, flags contradictions in mechanism papers like Singer et al. (1999) vs. Butterweck (2003). Writing Agent employs latexEditText for review drafting, latexSyncCitations for 250M+ OpenAlex bibliography, latexCompile for publication-ready output, and exportMermaid for neurotransmitter pathway diagrams.

Use Cases

"Extract and plot effect sizes from St. John's wort depression trials in Linde 2008 Cochrane review."

Research Agent → searchPapers('Linde 2008') → Analysis Agent → readPaperContent → runPythonAnalysis (pandas/matplotlib for GRADE meta-analysis plot) → researcher gets CSV of effect sizes and visualized forest plot.

"Draft LaTeX review on Hypericum perforatum CYP interactions citing Obach 2000 and Jiang 2004."

Synthesis Agent → gap detection → Writing Agent → latexEditText → latexSyncCitations (Obach, Jiang) → latexCompile → researcher gets compiled PDF with synced references and interaction diagrams.

"Find code for hyperforin molecular dynamics simulations from pharmacology papers."

Research Agent → searchPapers('hyperforin simulation') → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets validated GitHub repos with simulation scripts and usage docs.

Automated Workflows

Deep Research workflow conducts systematic review of 50+ Hypericum papers starting with citationGraph on Linde et al. (2008), producing GRADE-graded structured report on efficacy. DeepScan applies 7-step analysis with CoVe checkpoints to verify mechanisms in Chatterjee et al. (1998) and Singer et al. (1999). Theorizer generates hypotheses on hyperforin Na+ uptake from Singer et al. (1999) literature synthesis.

Try Doxa for Hypericum Perforatum Pharmacology Research

Frequently Asked Questions

What is Hypericum perforatum pharmacology?

It studies bioactive compounds like hyperforin and hypericin from St. John's wort, their pharmacokinetics, neurotransmitter effects, and clinical applications in depression and infections.

What are key methods in this field?

Methods include clinical RCTs (Linde et al., 2008), in vitro CYP inhibition assays (Obach, 2000), and antibacterial MIC testing (Schempp et al., 1999; Saddiqe et al., 2010).

What are the most cited papers?

Top papers are Linde et al. (2008, 471 citations) on depression, Chatterjee et al. (1998, 444 citations) on hyperforin, and Obach (2000, 400 citations) on CYP interactions.

What open problems exist?

Challenges include extract standardization, predicting clinical CYP interactions from in vitro data, and resolving multiple antidepressant mechanisms (Butterweck, 2003; Singer et al., 1999).